CLLS vs. ALLO, OLMA, TRDA, BNTC, RNAC, MBX, SEPN, GLUE, PROK, and ATAI
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Allogene Therapeutics (ALLO), Olema Pharmaceuticals (OLMA), Entrada Therapeutics (TRDA), Benitec Biopharma (BNTC), Cartesian Therapeutics (RNAC), MBX Biosciences (MBX), Septerna (SEPN), Monte Rosa Therapeutics (GLUE), ProKidney (PROK), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry.
Cellectis vs.
Allogene Therapeutics (NASDAQ:ALLO) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation.
Cellectis received 130 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. However, 65.89% of users gave Allogene Therapeutics an outperform vote while only 65.09% of users gave Cellectis an outperform vote.
In the previous week, Allogene Therapeutics had 1 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Allogene Therapeutics and 6 mentions for Cellectis. Cellectis' average media sentiment score of 0.85 beat Allogene Therapeutics' score of 0.81 indicating that Cellectis is being referred to more favorably in the news media.
Allogene Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500.
Cellectis has higher revenue and earnings than Allogene Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Allogene Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -234.39%. Allogene Therapeutics' return on equity of -52.13% beat Cellectis' return on equity.
Allogene Therapeutics currently has a consensus price target of $9.29, indicating a potential upside of 452.91%. Cellectis has a consensus price target of $7.00, indicating a potential upside of 325.53%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Cellectis.
83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 24.3% of Allogene Therapeutics shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Allogene Therapeutics beats Cellectis on 10 of the 18 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
This page (NASDAQ:CLLS) was last updated on 4/30/2025 by MarketBeat.com Staff
Buy CLLS Stock Free CLLS Stock Alerts